From the Department of Nuclear Medicine, Shohadae Tajrish Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Clin Nucl Med. 2020 Oct;45(10):789-791. doi: 10.1097/RLU.0000000000003208.
Progression of prostate cancer and prostate-specific antigen (PSA) elevation are closely associated. In fewer than 1% of all cases, disease progression may occur despite low or undetectable PSA levels. In these conditions, androgen deprivation therapy is relatively ineffective, and the prostate cancer progresses very quickly. We present a 65-year-old man with non-PSA-secreting prostate cancer and widespread metastases with rather fair response to Lu-prostate-specific membrane antigen radioligand therapy.
前列腺癌的进展与前列腺特异性抗原（PSA）升高密切相关。在所有病例中，不到 1%的情况下，尽管 PSA 水平较低或无法检测到，疾病仍可能进展。在这些情况下，雄激素剥夺疗法效果相对较差，前列腺癌进展非常迅速。我们报告了一例 65 岁非 PSA 分泌性前列腺癌患者，广泛转移，对 Lu-前列腺特异性膜抗原放射性配体治疗有较好的反应。
